Fintel on MSN1d
BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation
Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...
NRx Pharmaceuticals initiated with a Buy at BTIG
BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...
BTIG upgrades Progyny to Buy on improving demand
BTIG upgraded Progyny (PGNY) to Buy from Neutral with a $28 price target The firm says the company’s demand is coming back up, the stock’s ...
Yahoo Finance5d
Humacyte price target lowered to $8 from $10 at BTIG
BTIG lowered the firm’s price target on Humacyte (HUMA) to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The firm cites the company’s increased share count for the ...
CrowdStrike upgraded by BTIG, citing 'dominance' in market
CrowdStrike (CRWD) was upgraded from Neutral to Buy by BTIG, and maintains a $431 price target on the stock. Market ...
BTIG Research Has Lowered Expectations for Ovid Therapeutics (NASDAQ:OVID) Stock Price
Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...
Nasdaq16d
BTIG Upgrades Progyny (PGNY)
As of March 19, 2025, the average one-year price target for Progyny is $27.71/share. The forecasts range from a low of $23.23 to a high of $35.70. The average price target represents an increase ...
History shows S&P 500 does well in April after a weak March, BTIG says
BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...
Why CrowdStrike Stock Is Flying Higher Today
Shares of CrowdStrike (NASDAQ: CRWD) surged higher on Monday. The move up comes as the S&P 500 and Nasdaq Composite had gained 0.2% and 0.3%, respectively. The cybersecurity company received a rating ...